This Article  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

JAMA. 1970;213(7):1109-1122.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Mass production of vaccine for meningitis delayed

Since the Army-developed (and Army-tested) vaccine has no license manufacturers appear reluctant to produce the vaccine in quantity

The new vaccine for Type C meningococcal meningitis is in a sort of administrative and scientific limbo. It may be some time before large stocks of a licensed product are available.

The Army began general, but limited, use of the vaccine several months ago. (JAMAMEDICAL NEWS211:1107 [Feb 16] 1970). The vaccine is, quite rightly, a source of Army pride. It was developed at the Army's Walter Reed Institute of Research, Washington, DC, by a team led by Malcolm Artenstein, MD, chief developer of the rubella vaccine. A series of laboratory and large-scale field trials have been successful. The vaccine produced a ten-fold reduction in the incidence of the disease, an antibody response in more than 90% of recipients, and virtually no side . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?